CD274 and neoplasm: Furthermore, research has demonstrated that combining CAR-T cell therapy with monoclonal antibodies targeting PD-1 or PD-L1 can significantly enhance the persistence, anti-tumor efficacy, and delay the exhaustion of CAR-T cells in vivo (120).